Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer drugs to treat birth defects

Identical mutations of the same genes can lead either to congenital malformations or to cancer, depending on their cellular and temporal context. The demonstration of activated RAS-ERK signaling in a mouse model of Apert syndrome suggests that drugs designed to inhibit this pathway in cancer may also delay the progression of several serious pediatric syndromes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: FGFR2 activation and the RAS-ERK pathway.

Katie Ris-Vicari


  1. Shukla, V., Coumoul, X., Wang, R.H., Kim, H.-S. & Deng, C.-X. Nat. Genet. 39, 1145–1150 (2007).

    Article  CAS  Google Scholar 

  2. Wilkie, A.O.M. et al. Nat. Genet. 9, 165–172 (1995).

    Article  CAS  Google Scholar 

  3. Ibrahimi, O.A. et al. Hum. Mol. Genet. 13, 2313–2324 (2004).

    Article  CAS  Google Scholar 

  4. Pollock, P.M. et al. Oncogene advance online publication 21 May 2007 (doi: 10.1038/sj.onc.1210529).

    Article  CAS  Google Scholar 

  5. Chen, L., Li, D., Li, C., Engel, A. & Deng, C-X. Bone 33, 169–178 (2003).

    Article  CAS  Google Scholar 

  6. Wang, Y. et al. Development 132, 3537–3548 (2005).

    Article  CAS  Google Scholar 

  7. Kim, D.H. & Rossi, J.J. Nat. Rev. Genet. 8, 173–184 (2007).

    Article  CAS  Google Scholar 

  8. Dailey, L., Ambrosetti, D., Mansukhani, A. & Basilico, C. Cytokine Growth Factor Rev. 16, 233–247 (2005).

    Article  CAS  Google Scholar 

  9. Wilkie, A.O.M. Cytokine Growth Factor Rev. 16, 187–203 (2005).

    Article  CAS  Google Scholar 

  10. Eswarakumar, V.P. et al. Proc. Natl. Acad. Sci. USA 103, 18603–18608 (2006).

    Article  CAS  Google Scholar 

  11. Perlyn, C.A., Morriss-Kay, G., Darvann, T., Tenenbaum, M. & Ornitz, D.M. Neurosurgery 59, 210–215 (2006).

    Article  Google Scholar 

  12. Ohren, J.F. et al. Nat. Struct. Mol. Biol. 11, 1192–1197 (2004).

    Article  CAS  Google Scholar 

  13. Kohno, M. & Pouyssegur, J. Ann. Med. 38, 200–211 (2006).

    Article  CAS  Google Scholar 

  14. Schubbert, S., Shannon, K. & Bollag, G. Nat. Rev. Cancer 7, 295–308 (2007).

    Article  CAS  Google Scholar 

  15. Solit, D.B. et al. Nature 439, 358–362 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wilkie, A. Cancer drugs to treat birth defects. Nat Genet 39, 1057–1059 (2007).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing